July 15, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ZOC2017217, an eye drop aimed at slowing or reversing the development of cataracts, is undergoing a pilot study ahead of a potential phase 3 trial, according to a press release from Lexitas Pharma Services and Ocusun. “Today, cataract surgery is the only established treatment for cataracts,” Nevin El-Nimri, OD, senior director of clinical and medical affairs at Lexitas Pharma Services, told
July 15, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Lexitas Pharma Services and Ocusun Enroll First Patient in a Pilot Study for an Upcoming Phase III Clinical Trial Evaluating…

Trials of vision-improving substances are showing good results, though so far only two have been authorized for use in the United…

A Turkish ophthalmologist’s experimental eye drop targeting Fuchs’ dystrophy, a corneal disease that can lead to blindness and…

MIAMI — Combining minimally invasive glaucoma surgery with pharmaceutical drug delivery is an option to lower IOP in patients who…

Two methods of cataract surgery — phacoemulsification and manual small-incision cataract surgery — can lead to “acute detrimental…

Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according to a…